Sentara Infusion Services: Drug Recall
Recall #D-0307-2023 · 12/27/2022
Class II: Risk
Recall Details
- Recall Number
- D-0307-2023
- Classification
- Class II
- Product Type
- Drug
- Recalling Firm
- Sentara Infusion Services
- Status
- Completed
- Date Initiated
- 12/27/2022
- Location
- Chesapeake, VA, United States
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 83 bags
Reason for Recall
Lack of sterility assurance
Product Description
Milrinone (a) 104MG IN 0.45% NS 130ML,(b) 108MG IN 0.45% NS 135ML, (c) 120MG IN 0.45% NS 150ML, (d) 136MG IN 0.45% NS 170ML, (e) 144MG IN 0.45% NS 180ML, (f) 160MG IN 0.45% NS 200ML, (g) 168MG IN 0.45% NS 210ML, (h) 192MG IN 0.45% NS 240ML, (i) 44MG IN 0.45% NS 55 ML, (j) 52MG IN 0.45% NS 65ML, (k) 56MG IN 0.45% NS 70ML, (l) 68MG IN 0.45% NS 85ML, (m) 84MG IN 0.45% NS 105ML, (n) 88MG IN 0.45% NS 110ML, (o) 92MG IN 0.45% NS 115ML, (p) 96MG IN 0.45% NS 120ML, ionotrop, Rx Only, use with a Curlin or no pump, Sentara Home Infusion Pharmacy Services, 535 Independence Pkwy, Ste 300, Chesapeake, VA 23320
Distribution Pattern
Dispensed to Patients Nationwide.
Other Recalls by Sentara Infusion Services
- Class II: Risk 12/27/2022
- Class II: Risk 12/27/2022
- Class II: Risk 12/27/2022
- Class II: Risk 12/27/2022
- Class II: Risk 12/27/2022
Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.